8-K 1 tm2013489-1_8k.htm FORM 8-K






Washington, D.C. 20549









Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934


Date of Report (Date of earliest event reported):

March 23, 2020





(Exact name of registrant as specified in its charter)




Québec  001-38899  Not applicable
(state or other jurisdiction of incorporation)  (Commission File Number)  (I.R.S. Employer Identification No.)
1111 Dr. Frederik-Philips Boulevard, Suite 420      
Montréal, Québec CA     H4M 2X6
(Address of principal executive offices)     (Zip Code)


Registrant's telephone number, including area code: (514) 336-0444


(Former name or former address, if changed since last report.)




Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):


¨  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


¨  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


¨  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


¨  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Securities registered pursuant to Section 12(b) of the Act:


Title of each class  Trading Symbol(s)  Name of each exchange on which registered
Common Shares  MIST  The Nasdaq Stock Market LLC


Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b–2 of the Securities Exchange Act of 1934 (§ 240.12b–2 of this chapter).


Emerging growth company x


If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  x






Item 8.01. Other Events.


On March 23, 2020, Milestone Pharmaceuticals Inc. (the “Company”) issued a press release announcing topline results from its Phase 3 NODE-301 trial of etripamil for the treatment of paroxysmal supraventricular tachycardia. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.


The Company will host a conference call and webcast to discuss the results of the NODE-301 trial at 5:00 p.m. ET on March 23, 2020. The live call may be accessed by phone by dialing (800) 529-3311 (domestic) or (470) 495-9164 (international). The conference ID is 6152207. A live audio webcast of the event may also be accessed through the "Investors" section of the Company’s website at www.milestonepharma.com. A replay of the webcast will be available for 30 days following the event. The information contained in, or that can be accessed through, the Company’s website is not a part of this filing. A copy of the slide presentation to be used by the Company during the conference call is filed as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated herein by reference.


Item 9.01. Financial Statements and Exhibits.


(d) Exhibits.


99.1  Press release, dated March 23, 2020
99.2  Conference Call Presentation, dated March 23, 2020








Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


  By: /s/ Amit Hasija
    Amit Hasija
    Chief Financial Officer
    Principal Financial Officer


Dated: March 23, 2020